Direct-acting antivirals (DAAs) have dramatically improved the management of chronic hepatitis C (CHC). In this study, we investigated the effects of hepatitis C virus clearance on markers of systemic inflammation measured in plasma samples from CHC patients before, during and after DAA therapy. We identified a plasma soluble protein profile associated with CHC. Successful DAA therapy rapidly normalised the plasma inflammatory milieu, with the notable exception of soluble (s)CD163, a marker of macrophage activation, which remained elevated after viral clearance and segregated patients with high and low levels of cirrhosis. Patients who received DAA in combination with Ribavirin maintained elevated levels of CXCL10, consistent with an immune-stimulatory role of Ribavirin. As anticipated, DAA-treated patients experienced durable improvement in liver fibrosis measurements. Interestingly, pre-treatment levels of fatty acid-binding protein 4 (FABP4) were inversely associated with reduction of APRI and FIB-4 scores during treatment. Together, these results support the notion of a rapid restoration of many aspects of the inflammatory state in CHC patients in response to DAA therapy. Furthermore, the associations with sCD163 and FABP4 warrant further investigation into the role of macrophages in residual liver disease and fibrosis resolution after viral clearance.
Results
Plasma cytokine alterations associated with CHC and evolution during DAA therapy. To investigate the impact of HCV clearance on the immune system, 28 CHC patients were sampled before, during and after successful DAA treatment. In addition, blood samples from 20 healthy donors (HD), and 12 patients suffering from alcohol-induced cirrhosis (AC) were included as non-HCV infected comparison groups (Table 1) . Plasma concentrations of 25 soluble factors, all known to be related to the immune response or inflammation, were measured in each plasma sample (Supplementary Dataset). Out of the 25 soluble factors measured, four were significantly different (p < 0.05) between HD and CHC patients who were going to initiate IFN-free DAA therapy: CCL5, CXCL10, sCD14 and sCD163 ( Fig. 1a ). CCL5 was detected at lower levels (p = 0.0095), whereas CXCL10, sCD14 and sCD163 were higher in the CHC patients compared to HD (p < 0.0001, p = 0.0095 and p < 0.0001, respectively). Interestingly, there were no significant differences in CCL5 and CXCL10 levels between CHC patients and AC patients (p = 0.4764 and 0.0964), but sCD14 and sCD163 were significantly higher in CHC patients compared to AC (p = 0.0346 and 0.0489, respectively; Fig. 1a ).
Upon start of DAA therapy, differences with HD were quickly reduced ( Fig. 1b) , in contrast to the pattern observed in a previously treated cohort of CHC patients who received pegylated-IFN therapy and successfully achieved SVR ( Supplementary Fig. S1 ). At follow-up (FU) after completion of DAA therapy, both CCL5 and sCD14 were restored to levels comparable to HD, whereas CXCL10 and sCD163, although significantly decreased compared to BL, remained significantly elevated in comparison to HD (p = 0.0138 and p < 0.0001, respectively; Fig. 1c ).
Effect of Ribavirin on plasma cytokine profiles.
In our cohort, half of the patients who underwent DAA therapy received RBV as part of their treatment regimen ( Supplementary Fig. 2 ). We therefore stratified CHC patients according to the use of RBV to assess possible effects on plasma cytokine levels ( Fig. 2 ). There were no other significant differences before treatment between these two subgroups regarding age, BMI, liver health indicators (ALT, AST, albumin, bilirubin, PT-INR, thrombocytes, LSM) or any of the measured soluble markers. The patients that received RBV-free therapy quickly normalised all soluble factors in their plasma except for sCD163, which remained elevated throughout treatment. In contrast, patients that received RBV in combination with DAA maintained elevated levels of both CXCL10 and sCD163 ( Fig. 2a,b ). Six months after the end of therapy, sCD163 remained significantly elevated in both subgroups (p = 0.0158 and p = 0.0004), whereas CXCL10 was significantly elevated only in the group that received RBV (p = 0.0012, Fig. 2c ).
Levels of sCD163 distinguish patients with different degrees of liver cirrhosis throughout DAA therapy.
To assess whether the stage of liver disease was associated with the plasmatic protein profile, we stratified cirrhotic patients in the DAA group according to Child Pugh class. There were 18 patients classified as Child Pugh A and 7 patients classified as Child Pugh B. Although differences with HD seemed more pronounced in the Child B group (Fig. 3a) , those differences were also reduced upon start of therapy, with the exception of sCD163, which remained elevated and significantly different between the 2 subgroups throughout treatment ( Fig. 3b ). Even 6 months after successful therapy, sCD163 remained elevated in Child Pugh A patients (p = 0.0103) and even higher in Child Pugh B patients (p < 0.0001, Fig. 3c ). We also investigated possible associations between levels of sCD163 at the FU time point, and various indicators of liver health and found significant correlations with AST levels (ρ = 0.44, p = 0.0198), Albumin (ρ = −0.48, p = 0.0101) and prothrombin time (PT-INR, ρ = 0.41, p = 0.0301, Fig. 3d ). Thus, elevated sCD163 levels seem associated with liver disease and remain elevated in patients with advanced cirrhosis despite successful clearance of HCV with DAA therapy.
IFN-free DAA combinations improve fibrosis indicators.
Liver stiffness measurements were available from time points before and after therapy in 18 of the 28 DAA-treated patients (two non-cirrhotic, 14 Child Pugh A and two Child Pugh B). Mixed effects models of paired LSMs demonstrated a significant decrease in stiffness values (p < 0.0001), between baseline and follow-up measurements in the DAA group. The decrease was significant in the Child Pugh A subgroup of patients (p = 0.0003), and there was a similar trend in Child Pugh B patients ( Fig. 4a ). This pattern indicated decreased liver fibrosis and inflammation. Since DAA therapy efficiently eliminates the virus and quickly normalises most aspects of the cytokine milieu in plasma, it is likely that this treatment reduces liver inflammation and a decrease in LSM may thus be insufficient to conclude that there is a decrease in fibrosis. We therefore calculated APRI and FIB-4 scores for all treated patients. Both APRI and FIB-4 decreased significantly by EOT (p < 0.0068 and p = 0.0038, respectively), and this effect was maintained at follow-up (p = 0.0061 and p = 0.0010, respectively) ( Fig. 4b,c ). This pattern reached significance in the Child Pugh A patient subgroup with a similar trend in Child Pugh B patients (Fig. 4b,c ). These observations are consistent with the notion that DAA therapy reduces liver fibrosis, including in patients with advanced cirrhosis. In support of these results, six out of seven patients classified as Child Pugh B before the start of therapy were re-classified as Child Pugh A at follow-up, further indicating an improvement of liver status. www.nature.com/scientificreports www.nature.com/scientificreports/ Baseline levels of soluble FABP4 are associated with improvement of fibrosis indicators in response to DAA therapy. To investigate whether soluble plasma markers might be associated with fibrosis reduction, we performed Spearman correlation analyses between baseline levels of the 25 cytokines and the reduction in LSM, APRI and FIB-4 scores observed at FU ( Fig. 5 ). IL-18 levels at baseline correlated positively with LSM reduction (ρ = 0.54, p = 0.028), and FABP4 levels at baseline correlated negatively with reductions in both APRI (ρ = −0.53, p = 0.0035) and FIB-4 (ρ = −0.65, p = 0.0002). To investigate whether those correlations may be driven primarily by single components of the APRI and FIB-4 scores, we analysed correlations between FABP4 and platelet count increase and decrease in liver enzymes. Although FABP4 correlated significantly with platelet count increase (ρ = −0.48, p = 0.0097) and AST decrease (ρ = −0.45, p=0.0153; Supplementary Fig. S3 ), those correlations were weaker than the correlation with both composite scores, suggesting that FABP4 levels are associated with the reduction in liver disease.
Discussion
Residual liver disease and risk of developing HCC are concerns in patients that have cleared their HCV infection, and it is therefore important to understand the dynamics of systemic and hepatic inflammation during and after successful DAA treatment. Here, we identify differences in the plasma cytokine milieu of HD and CHC patients, and show that DAA therapy rapidly reduces those differences with the exception of sCD163. Levels of sCD163 also distinguish patients with different levels of cirrhosis. We also observe that patients who receive RBV seem to maintain elevated plasma levels of CXCL10, consistent with an immune-stimulatory role of RBV. Finally, we find a significant association between baseline levels of FABP4 and subsequent reduction in APRI and FIB-4 measurements during DAA treatment, suggesting a link between FABP4 plasma levels and liver disease reduction.
Our data set identified clear differences in plasma inflammatory markers between CHC patients and HD. CCL5 was reduced in CHC patients whereas CXCL10, sCD14 and sCD163 were elevated. CXCL10 is associated with viral load and HCV triggers its production via NF-κB activation 12 . Soluble CD14 is a marker of monocyte activation 13 , whereas sCD163 is a marker of macrophage activation 14 , and all these three markers are associated with liver fibrosis in untreated CHC [15] [16] [17] . However, elevated levels of sCD14 and sCD163 are not specific to HCV infection as previously observed in AC [18] [19] [20] . Interestingly, in our cohort, although both sCD14 and sCD163 were elevated in AC, they were significantly higher in CHC patients, despite a lower proportion of Child Pugh B and C In contrast to IFN-containing regimens, which induced broad changes in the cytokine milieu, DAA therapy quickly reduced the differences in plasma protein levels observed with HD. This pattern likely reflects the very different mechanisms of action of the two treatments. DAA drugs specifically interfere with viral replication, whereas IFN is immune activating and modulates the expression of hundreds of IFN-regulated genes, which themselves can influence cytokine secretion via a complex network of interactions 21 . These findings are in accordance with recent work by Burchill et al., showing a rapid decrease in the expression of genes associated with inflammation in PBMCs of HCV infected patients undergoing DAA therapy 22 . Certain features of T-cell and NK cell phenotype and function are also restored following DAA therapy [23] [24] [25] [26] , supporting the idea of a general immune system normalisation after HCV clearance. However, recent studies also indicate that other immune cell traits, such as the appearance of regulatory T cells 27 , NK cell receptor repertoire diversity 28 www.nature.com/scientificreports www.nature.com/scientificreports/ of the cytokine milieu during DAA therapy and, notably, CXCL10 remained elevated throughout treatment 30 . Interestingly, all patients in that cohort received RBV in combination with DAA, and our observations indicate that patients who receive RBV maintain higher levels of CXCL10. Studies have also shown that RBV has immunomodulatory effects 31, 32 and can induce ISGs in vitro 33, 34 . In our study, only sCD163 remained significantly elevated in patients that received DAA regimen without RBV.
Levels of sCD163 were significantly decreased by DAA treatment, as described by others 35, 36 . However, levels remained significantly elevated in comparison to those seen in HD. This is in accordance with work by Mascia et al., www.nature.com/scientificreports www.nature.com/scientificreports/ showing sustained high levels of sCD163 in DAA-treated CHC patients 12 weeks after EOT 37 . Additionally, we observed significant correlations between levels of sCD163 at FU and multiple indicators of liver health (AST, Albumin and PT-INR). Taken together, these findings by us and others suggest that persistent macrophage activation could play a role in residual liver disease despite a general dampening of inflammation ( Fig. 6 ). Of note, the last timepoint evaluated in our study was 6 months after EOT, thus further studies would be required to assess whether elevated sCD163 reflects an irreversible consequence of CHC or a slower recovery of certain immune processes.
It is also important to understand the response of patients with more severe cirrhosis (Child Pugh B) to DAA combinations in comparison to patients with milder liver damage (Child Pugh A). Our data indicate that IFN-free DAA therapy normalises the cytokine profile, with the exception of sCD163, in both groups, and thus suggest that advanced liver damage is not a barrier to a normalised plasma cytokine milieu. Interestingly, six out of the seven Child Pugh B patients from our cohort were re-classified as Child Pugh A at the EOT, in line with improved liver function. We also observed a clear improvement in LSMs after treatment, as observed by others [38] [39] [40] . However, this measurement does not allow clear discrimination between reduction in liver inflammation, improvement of fibrosis, or a combination of the two. The predictive power of liver elasticity measurements for fibrosis can also be reduced following therapeutic eradication of HCV 41 . To complement the LSM data, we therefore investigated the evolution of APRI and FIB-4 scores during therapy and showed a clear reduction in both of these indicators of liver fibrosis. Nevertheless, further studies comprising liver biopsies will be required to determine the extent of liver regeneration after successful DAA therapy.
We also investigated associations between plasma proteins and improvement of liver fibrosis and found that baseline levels of FABP4 inversely correlated with the improvement in both APRI and FIB-4 observed after treatment. FABP4 is expressed in adipocytes and macrophages, and high serum concentrations of FABP4 are associated with inflammation and risk for metabolic and vascular diseases 42 . Recently, it was shown that increased FABP4 levels in the blood correlate with poor prognosis in cirrhosis 43 . In the same study, it was also shown that FABP4 gene expression was increased in cirrhotic livers and that liver macrophages seemed to be responsible for that increase. Interestingly, sCD163 is also released by macrophages and hepatic macrophages are known to play a critical role in liver inflammation, fibrosis and resolution of inflammation 44 . Investigating the mechanisms leading to sCD163 and FABP4 release during CHC may thus help better understand the mechanisms of fibrosis resolution during DAA therapy. Of note, CHC cohorts are often very heterogeneous groups and further research is needed to fully understand the influence of multiple factors (such as HCV genotype, fatty liver content, obesity, diabetes, etc.) on residual inflammation and liver disease.
In conclusion, these results support the notion of a rapid restoration of the inflammatory state in CHC in response to DAA therapy, but also warrant further investigations of the role of macrophage activation in liver disease reduction after clearance of HCV infection.
Methods

Patients.
To investigate the impact of HCV clearance on the immune system, CHC patients above 18 years of age scheduled to receive DAA therapy were sampled before, during and after treatment at the Department of Infectious Diseases and the Department of Gastroenterology and Hepatology at Karolinska University Hospital. Blood samples were collected from 28 CHC patients who received DAA therapy and successfully achieved SVR, and 13 CHC patients who received pegylated-IFN therapy and successfully achieved SVR. Exclusion criteria included concurrent Hepatitis B virus or HIV co-infections. In addition, blood samples from 20 HD, and 12 patients suffering from AC were included as non-HCV infected comparison groups. Of note, a proportion (64%) 
